Holley Aaron B, Boose Wesley D, Perkins Michael, Sheikh Karen L, Solomon Nancy P, Dietsch Angela M, Vossoughi Jafar, Johnson Arthur T, Collen Jacob F
Pulmonary/Sleep and Critical Care Medicine, San Antonio Military Medical Center, 3551 Roger Brooke Dr, San Antonio, TX.
US Naval Hospital Guam, PSC 490 Box 208, FPO, AP, Guam.
Mil Med. 2018 Sep 1;183(9-10):e370-e377. doi: 10.1093/milmed/usx224.
Following reports of respiratory symptoms among service members returning from deployment to South West Asia (SWA), an expert panel recommended pre-deployment spirometry be used to assess disease burden. Unfortunately, testing with spirometry is high cost and time-consuming. The airflow perturbation device (APD) is a handheld monitor that rapidly measures respiratory resistance (APD-Rr) and has promising but limited clinical data. Its speed and portability make it ideally suited for large volume pre-deployment screening. We conducted a pilot study to assess APD performance characteristics and develop normative values.
We prospectively enrolled subjects and derived reference equations for the APD from those without respiratory symptoms, pulmonary disease, or tobacco exposure. APD testing was conducted by medical technicians who received a 10-min in-service on its use. A subset of subjects performed spirometry and impulse oscillometry (iOS), administered by trained respiratory therapists. APD measures were compared with spirometry and iOS.
The total study population included 199 subjects (55.8% males, body mass index 27.7 ± 6.0 kg/m2, age 49.9 ± 18.7 yr). Across the three APD trials, mean inspiratory (APD-Ri), expiratory (APD-Re), and average (APD-Ravg) resistances were 3.30 ± 1.0, 3.69 ± 1.2, and 3.50 ± 1.1 cm H2O/L/s. Reference equations were derived from 142 clinically normal volunteers. Height, weight, and body mass index were independently associated with APD-Ri, APD-Re, and APD-Ravg and were combined with age and gender in linear regression models. APD-Ri, APD-Re, and APD-Ravg were significantly inversely correlated with FEV1 (r = -0.39 to -0.42), FVC (r = -0.37 to -0.40), and FEF25-75 (r = -0.31 to -0.35) and positively correlated with R5 (r = 0.61-0.62), R20 (r = 0.50-0.52), X5 (r = -0.57 to -0.59), and FRES (r = 0.42-0.43). Bland-Altman plots showed that the APD-Rr closely approximates iOS when resistance is normal.
Rapid testing was achieved with minimal training required, and reference equations were constructed. APD-Rr correlated moderately with iOS and weakly with spirometry. More testing is required to determine whether the APD has value for pre- and post-deployment respiratory assessment.
在有从部署地返回西亚西南部(SWA)的军人出现呼吸道症状的报告后,一个专家小组建议使用部署前肺活量测定法来评估疾病负担。不幸的是,肺活量测定法检测成本高且耗时。气流扰动装置(APD)是一种手持式监测仪,可快速测量呼吸阻力(APD-Rr),其临床数据虽有前景但有限。其速度和便携性使其非常适合大规模的部署前筛查。我们进行了一项试点研究,以评估APD的性能特征并制定标准值。
我们前瞻性地招募了受试者,并从无呼吸道症状、肺部疾病或烟草暴露史的受试者中得出了APD的参考方程。APD检测由接受过10分钟使用培训的医学技术人员进行。一部分受试者进行了肺活量测定和脉冲振荡法(iOS)检测,由训练有素的呼吸治疗师操作。将APD测量值与肺活量测定法和iOS测量值进行比较。
研究总人群包括199名受试者(55.8%为男性,体重指数27.7±6.0kg/m²,年龄49.9±18.7岁)。在三项APD试验中,平均吸气(APD-Ri)、呼气(APD-Re)和平均(APD-Ravg)阻力分别为3.30±1.0、3.69±1.2和3.50±1.1cmH₂O/L/s。参考方程来自142名临床正常的志愿者。身高、体重和体重指数与APD-Ri、APD-Re和APD-Ravg独立相关,并在多元线性回归模型中与年龄和性别相结合。APD-Ri、APD-Re和APD-Ravg与第一秒用力呼气容积(FEV₁,r=-0.39至-0.42)、用力肺活量(FVC,r=-0.37至-0.40)和25%-75%用力呼气流量(FEF₂₅-₇₅,r=-0.31至-0.35)显著负相关,与R5(r=0.61-0.62)、R20(r=0.50-0.52)、X5(r=-0.57至-0.59)和呼吸阻力(FRES,r=0.42-0.43)显著正相关。布兰德-奥特曼图显示,当阻力正常时,APD-Rr与iOS密切近似。
以最少的培训要求实现了快速检测,并构建了参考方程。APD-Rr与iOS中度相关,与肺活量测定法弱相关。需要更多检测来确定APD在部署前和部署后呼吸评估中是否有价值。